HK Stock Market Move | AV CONCEPT HOLD (00595) surges over 15% after profit alert, expects interim profit exceeding HK$400 million, a 5.4-fold year-on-year increase.
AV CONCEPT HOLD (00595) surged over 15%, up 15.22% as of press time, at HK$1.06, with a turnover of HK$5.746 million.
AV CONCEPT HOLD (00595) rose over 15%, up 15.22% as of press time to HK$1.06, with turnover of HK$5.746 million.
On the news front, AV CONCEPT HOLD issued a positive profit alert last night, expecting consolidated profit attributable to owners of the company of over HK$400 million for the six months ended September 30, 2026, compared with approximately HK$62.4 million in the same period last year, an increase of 541% year-on-year. The board considers that the expected increase in profit is attributable to an increase in gross profit margin, mainly driven by growth in the semiconductor distribution segment, as well as an increase in the share of profits and losses of joint ventures and associates, mainly due to improved performance of the joint ventures.
Related Articles

HK Stock Market Move | ANHUIEXPRESSWAY (00995) fell more than 7% in morning trading; plans to issue additional H shares to raise nearly HK$700 million, most of which will be used to invest in and operate expressways.

HK Stock Market Move | CSPC PHARMA (01093) rises over 4%; net profit for the first three quarters more than doubles year-on-year; licensing fee revenue surges 307%

HK Stock Market Move | INNOVENT BIO (01801) rises over 2%; partner Ollin to be acquired by Johnson & Johnson; core Phase III asset IBI/OLN324 to be incorporated into J&J's pipeline.
HK Stock Market Move | ANHUIEXPRESSWAY (00995) fell more than 7% in morning trading; plans to issue additional H shares to raise nearly HK$700 million, most of which will be used to invest in and operate expressways.

HK Stock Market Move | CSPC PHARMA (01093) rises over 4%; net profit for the first three quarters more than doubles year-on-year; licensing fee revenue surges 307%

HK Stock Market Move | INNOVENT BIO (01801) rises over 2%; partner Ollin to be acquired by Johnson & Johnson; core Phase III asset IBI/OLN324 to be incorporated into J&J's pipeline.






